GSK-Galapagos' autoimmune disease drug enters midstage trials

02/6/2013 | Pharmaceutical Business Review Online · Reuters

GlaxoSmithKline is preparing midstage trials to assess the experimental drug GSK2586184 in patients with systemic lupus erythematosus and chronic plaque psoriasis. GSK2586184, a selective JAK1 molecule, was identified under Galapagos and GSK's osteoarthritis collaboration.

View Full Article in:

Pharmaceutical Business Review Online · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN